The Latest Cardiac and Vascular News
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently in an ongoing global Phase 2b clinical trial in patients […]
Atlas, Carta’s AI-assisted data abstraction software, seamlessly automates submission to the ACC’s CathPCI clinical data registry, allowing healthcare organizations to maximize the benefits of registry contributions SAN FRANCISCO–(BUSINESS WIRE)–Carta Healthcare, a provider of artificial intelligence (AI)-powered clinical data abstraction technology and services, today announced that it is now a certified […]
American Heart Association consortium advances development of evidence-based health tech solutions PORTLAND, Maine–(BUSINESS WIRE)–Ginkgo Heart, LLC, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The […]
– New labeling approval for Abbott’s XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR) – The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval […]
Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia. Javier San Martin, M.D., chief medical officer at […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed’s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular […]
Large-scale phase 3 trial shows significant reduction in cardiovascular and kidney disease risk First public reveal of results from large-scale, Sanofi-led global phase 3 trial for efpeglenatide Hanmi aims to achieve new innovations with biologic SEOUL, South Korea, June 29, 2021 /PRNewswire/ — Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, […]
AngelMed Guardian® System prompts high-risk ACS patients to seek medical care EATONTOWN, N.J., June 28, 2021 /PRNewswire/ — Angel Medical Systems, Inc., (dba AngelMed) a proactive diagnostics company focused on the advancement of long-term management of high-risk coronary disease, announced today the FDA approval of the second-generation AngelMed Guardian® device. The AngelMed Guardian System […]
SAVANNAH, Ga., June 28, 2021 /PRNewswire/ — Red One Medical, a proven government contractor providing best-in-class medical supplies to Veterans Affairs and the Department of Defense, is proud to exclusively partner with Prytime Medical Devices, Inc. (The REBOA Company™), a privately held medical technology company focused on minimally invasive solutions for trauma. As […]
